Trials / Completed
CompletedNCT02015481
Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients
Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Bioblast Pharma Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of this study is to assess the Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cabaletta |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2013-12-19
- Last updated
- 2017-10-17
- Results posted
- 2017-08-23
Locations
4 sites across 3 countries: United States, Canada, Israel
Source: ClinicalTrials.gov record NCT02015481. Inclusion in this directory is not an endorsement.